BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023

Rhea-AI Summary

BioCardia, Inc. will provide a corporate update and report its financial results for Q3 and 9 months ended September 30, 2023. The conference call will take place on November 8, 2023, at 4:30 PM ET. Participants can register for the conference call through the provided link. The call will also be available through a live webcast, with a replay available afterwards.

SUNNYVALE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three and nine months ended September 30, 2023 by conference call on Wednesday, November 8, 2023 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session.

Participants can register for the conference by navigating to https://dpregister.com/sreg/10184161/faf88f5b32. Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=bPAksYvP.

A webcast replay of the call will be available approximately one hour after the end of the call at the above links. A telephonic replay of the call will be available and may be accessed by calling 1-877-344-7529 (domestic), 1-412-317-0088 (international) or 855-669-9658 (Canada) by using access code 8151652.

About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is a developer of two biotherapeutic platforms – the CardiAMP autologous bone marrow derived mononuclear cell therapy for cardiovascular indications, and the NK1R+ allogeneic bone marrow derived mesenchymal stem cell therapies for cardiovascular and pulmonary diseases.  These platforms underly four product candidates, each with the potential to meaningfully benefit millions of patients. Three of these investigational therapies are enabled by the Company’s proprietary biotherapeutic delivery platforms, which the Company also selectively partners to other biotherapeutic development firms. For more information visit http://www.biocardia.com.

MEDIA CONTACT:
Miranda Peto, Marketing / Investor Relations
mpeto@biocardia.com
(650) 226-0120

INVESTOR CONTACT:
David McClung, Chief Financial Officer
investors@biocardia.com
(650) 226-0120

FAQ

When will BioCardia provide a corporate update and report its financial results?

BioCardia will provide a corporate update and report its financial results for the three and nine months ended September 30, 2023 on November 8, 2023.

How can participants register for the conference call?

Participants can register for the conference call by navigating to the provided link.

What are the dial-in numbers for the conference call?

Interested parties within the U.S. should call 1-833-316-0559, and international callers should call 1-412-317-5730.

When should callers dial in for the conference call?

All callers should dial in approximately 10 minutes prior to the scheduled start time.

How can participants access the live webcast of the conference call?

Participants can access the live webcast through the provided link.

When will the webcast replay be available?

A webcast replay of the call will be available approximately one hour after the end of the call.

How can participants access the telephonic replay of the call?

Participants can access the telephonic replay by calling the provided numbers and using the access code.